Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?

Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but ca...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 21; no. 1; p. 580
Main Authors:	Chauhan, Aman, Das, Satya, Miller, Rachel, Luque, Laura, Cheuvront, Samuel N, Cloud, James, Tarter, Zach, Siddiqui, Fariha, Ramirez, Robert A, Anthony, Lowell
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 20-05-2021 BioMed Central BMC
Subjects:	Amino acid oral rehydration solution Amino acids Antidiarrheals Cancer therapies Care and treatment Chemotherapy Diarrhea Excess bowel movements Health aspects Hospital costs Hypotheses Neuroendocrine tumors Oncology Patients Pharmacology, Experimental Radiation Rehydration United States United States > US Diarrhea Excess bowel movements Amino acid oral rehydration solution Neuroendocrine tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration solution (enterade® Advanced Oncology Formula) was found to have anti-diarrheal properties in preclinical models. A retrospective chart review of all NET patients treated with enterade® AO was performed after IRB approval. Ninety-eight NET patients who had received enterade® AO at our clinic from May 2017 through June 2019 were included. Patients (N = 49 of 98) with follow up data on bowel movements (BMs) were included for final analysis. Eighty-four percent of patients (41/49) had fewer BMs after taking enterade® AO and 66% (27/41) reported more than 50% reduction in BM frequency. The mean number of daily BMs was 6.6 (range, 3-20) at baseline before initiation of therapy, while the mean number of BMs at 1 week time point post enterade® AO was 2.9 (range, 0-11). Our retrospective observations are encouraging and support prospective validation with appropriate controls in NET patients. This is first published report of the potential anti-diarrheal activity of enterade® AO in NET patients.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1471-2407 1471-2407
DOI:	10.1186/s12885-021-08315-4